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Abstract
Background: The aim of this study was to evaluate implantable loop recorders (ILRs) in an unselected 
cohort in order to determine diagnostic yield, time to pacemaker/implantable cardioverter-defibrillator 
(ICD) implantation, predictors thereof, safety issues, and syncope management including usage of 
preceding diagnostic tools.
Methods: Patients who underwent ILR evaluation in any of three centers in Region Gävleborg, Swe-
den, between April 2007 and April 2013 were included and their medical records retrieved. Logistic 
regression was used to evaluate predictors of pacemaker/ICD outcome expressed as odds ratios (ORs) 
and Kaplan-Meier estimates for time-dependent analysis. 
Results: A total of 173 patients (52.6% females) with a mean age of 56.2 years received an ILR dur-
ing a mean follow-up of 605 days. In the 146 patients evaluated for syncope/presyncope, 28.1% received  
a pacemaker (n = 39) or ICD (n = 2). The cumulative incidence at 6, 12, and 18 months were 8.8%, 
21.3%, and 26.7%, respectively. Age > 75 years was the only significant predictor for outcome (p = 0.010)  
and the following variables showed a tendency toward significance: abnormal elevation of the biomarker 
B-type natriuretic peptide (OR 2.05, p = 0.100), a history of trauma (OR 1.71, p = 0.179), and patho-
logic electrocardiogram (OR 1.68, p = 0.231). A computerized tomography of the skull was performed 
in 52.1% of the syncope cases.
Conclusions: In syncope evaluation in an unselected cohort, 28.1% were diagnosed with an arrhyth-
mia necessitating a pacemaker/ICD. The only significant predictor was advanced age. Time to diag-
nosis is unpredictable and prolonged ILR monitoring is warranted in addition to optimal use of other 
diagnostic tools. (Cardiol J 2018; 25, 3: 363–370)
Key words: cardiac arrhythmia, implantable loop recorder, electrocardiography  
monitoring, pacemaker, syncope 
Introduction
Cardiac arrhythmias may be challenging to 
detect and an implantable loop recorder (ILR) of-
fers  prolonged diagnostic evaluation. Syncope is 
a transient loss of consciousness caused by cerebral 
hypoperfusion and typically occurs suddenly, has 
a short duration and complete recovery [1]. In syn-
cope caused by a cardiac arrhythmia, the prognosis 
is worse and up to a third of patients die within 
a year [2]; elderly patients seem to be especially 
at risk [3]. However, independent of its cause and 
prognosis, syncope may adversely affect quality 
of life because of anxiety, restricted activities like 
driving, and the risk of trauma. For patients with 
suspected syncope, it is crucial to get a detailed 
364 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 3
history and extensive evaluation is sometimes 
necessary, including the use of an ILR [4]. Almost 
half of the population will faint at least once over 
the course of a lifetime [5], with peak incidences 
in adolescence and old age, and syncope accounts 
for 1–3% of emergency department visits [2]. Even 
though guidelines stress the role of ILR evaluation 
in syncope, in actual clinical practice the number 
of patients indicated for an ILR is about 4 times 
higher than the number who actually receive one 
and about one-third of those who do receive an ILR 
do not meet the criteria for one as set forth by the 
guidelines [1, 6]. At a tertiary center, ILRs were 
used in 5% of referrals for syncope, in 28% of cases 
of unexplained syncope [7] and in 1% of emergency 
visits [8]. In addition to syncope management, ILR 
are used to detect atrial fibrillation (AF) or explain 
symptoms such as palpitations, dizziness, and 
falls [1, 9–11]. Among syncope patients an ILR may 
reveal a significant bradycardia (asystole, sinus 
arrest, high-degree atrioventricular block) or 
a ventricular tachycardia possibly requiring pace-
maker or implantable cardioverter-defibrillator 
(ICD) treatment, respectively [12, 13]. ILRs may 
also detect supraventricular tachycardias, which 
may result in such treatments as antiarrhythmic 
drug therapy, anticoagulation therapy, or an ablation 
procedure. The absence of cardiac arrhythmia may 
lead to further investigation or reassurance after 
a long-term follow-up period. Approximately a fifth 
of the patients in reported cohorts over the last few 
years underwent pacemaker implantation due to 
ILR findings of bradycardia [10, 14–17]. However 
these studies may be prone to selection bias as 
they were conducted at tertiary centers, which 
act as referral centers, while other studies use 
a prospective design, including specific protocols 
for disease management. Therefore, ILR evalu-
ation from these studies may not necessarily be 
generalized to other settings.
The objectives of this ILR evaluation were to 
determine diagnostic yield, time to pacemaker/ICD 
and predictors thereof, safety issues, and syncope 
management, including the use of preceding diag-
nostic tools.
Methods
Setting
All consecutive patients who underwent an 
ILR procedure in Region Gävleborg between 
April 2007 and April 2013 were included. Region 
Gävleborg has a current catchment area of 281,815 
inhabitants and 3 hospitals (Bollnäs, Gävle, and 
Hudiksvall), which are all non-university hospitals 
that evaluate syncope patients, including the use of 
ILR procedures, as a diagnostic tool [18]. 
Data sources and ethics
The patients were identified using the medi-
cal record system, including the hospital-based 
surgery database that covers all ILR procedures. 
The daily updated Swedish population Census Bu-
reau Register was used to ascertain if the patient 
was deceased and living patients were contacted 
(including three reminders and phone contact) to 
gain informed consent in order to read the relevant 
portions of their medical records. Data acquisition 
according to a predefined protocol of variables was 
performed by an experienced physician (MO) and 
validated by a cardiologist (PM). The Regional 
Ethical Committee in Uppsala approved the study 
(protocol number 2016/098), which was conducted 
in compliance with the Declaration of Helsinki.
Statistical analysis
Descriptive data were expressed as frequen-
cies and percentages. Continuous variables were 
summarized as means including standard devia-
tions (SDs), median, 25th, and 75th percentiles, and 
compared using t-tests. Categorical variables were 
compared using c2 test. Kaplan-Meier analyses and 
cumulative incidences were used to report time 
from first ILR procedure to outcome. An odds ratio 
(OR) with a 95% confidence interval (CI) was cal-
culated for a potential predictor of outcome in uni-
variable analyses followed by a multivariable model 
using  logistic regression. A two-sided p-value of 
< 0.05 was considered statistically significant. The 
database in Excel 2010 (Microsoft Corporation, 
Redmond, WA) was imported into SPSS version 
22 (IBM, Armonk, NY), and graphical presentation 
was made using R (R Core Team, 2014).
ILR procedure and follow-up
The ILR device was typically inserted sub-
cutaneously in the left parasternal area in a short 
procedure (a few minutes in duration) under local 
anesthesia. The patients received a Medtronic 
Reveal™ ILR (Minneapolis, MN): Reveal Dx™, Re-
veal XT™, and Reveal Plus™ or a St. Jude Medical 
Confirm™ ILR (St. Paul, MN) (n = 6). The remote 
monitoring function was available and used in 46 
(26.6%) of the cases, preferably during the latter 
period of the study. Activation of rhythm-storage 
can be done by the patient or a bystander but may 
also be carried out automatically according to pro-
grammed criteria of arrhythmias. Adjustment of 
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the programmed sensitivity setting was sometimes 
necessary. Atrial tachycardias were subdivided into 
AF, atrial flutter, and ectopic atrial tachycardia.
Results
Patient characteristics
During the 6-year period, a total of 210 pa-
tients received ILR evaluation and after consenting 
to participate in the study, 82.4% of these were 
analyzed (n = 173), whose baseline characteristics 
are summarized in Table 1. Their mean age at ILR 
implant was 56.2 years and ranged from 16 to 90 
years with a median of 60.0 years and 25th percen-
tiles 42 years, and 75th percentiles 73 years. Around 
half (n = 91; 52.6%) were females and mean age 
did not differ with regard to sex (58.6 years vs. 
54.0 years, p = 0.132). Mean age and sex distribu-
tion were similar between the 3 centers (Gävle: 
n = 90; 52.5%; p = 0.433; Hudiksvall: n = 40; 
66.2%; p = 0.450 Bollnäs: n = 43; 54.6%, p = 0.581). 
The main indication for ILR evaluation was 
a composite indication of syncope (n = 146; 84.4%), 
which included presyncope (n = 11; 6.4%), single syn-
cope (n = 24; 13.9%), or multiple syncope (n = 111; 
64.2%). Other indications of ILR were palpitations 
(n = 15; 8.7%), AF/cerebral infarction (n = 6; 
3.5%), atrioventricular block (n = 2; 1.2%), sinus 
node dysfunction (n = 3; 1.7%), and nonsustained 
ventricular tachycardia (n = 1; 0.6%). 
Diagnostic work-up of syncope
In taking the history of patients with syncopal 
episodes, the following circumstances were noted: 
trauma (n = 51), prodromal symptoms (n = 67), 
seizure (n = 10), and body posture (upright, n = 70; 
supine, n = 6; sitting n = 69; unknown, n = 28). 
Several patients performed a computerized tomog-
raphy (CT) (n = 79) of the skull or cardiac magnetic 
resonance imaging (n = 12) as part of syncope 
evaluation. A head-up tilt test (HUT) test was per-
formed in 4 patients as part of the syncope evalu-
ation. Notably, carotid sinus massage was carried 
out as part of clinical physical examination in 27 
(15.6%) patients at any time after a syncopal spell. 
Arrhythmia monitoring included Holter monitor-
ing or ambulatory electrocardiogram (ECG) in the 
ward and in a minority of cases additional recorders 
were used, such as  Zenicor™ (n = 14) or King of 
Hearts Express™ (n = 5). In Table 2, diagnostic 
tools used before ILR is summarized with regard 
to syncope and miscellaneous indications.
Follow-up time
The follow-up time with ILR monitoring varied 
from 3 to 1,482 days. In total, the cohort was moni-
Table 1. Clinical characteristics of 173 implantable loop recorder patients with regard to syncope and 
miscellaneous indications.
Variable All patients (n = 173) Syncope (n = 146) Miscellaneous (n = 27)
Age, mean (standard deviation [SD]) 56.2 (SD 19.9) 56.4 (SD 20.8) 54.8 (SD 14.1)
Male sex 82 (47.4%) 67 (45.9%) 15 (55.6%)
Diabetes 8 (4.6%) 7 (4.8%) 1 (3.7%)
Smoker 24 (13.9%) 18 (12.3%) 6 (22.2%)
Depression 12 (6.9%) 12 (8.2%) 0 (0%)
Polyneuropathy 2 (1.2%) 2 (1.4%) 0 (0%)
Migraine 8 (4.6%) 7 (4.8%) 1 (3.7%)
Epilepsy 1 (0.6%) 1 (0.7%) 0 (0%)
Stroke/transitory ischemic attack 21 (12.1%) 15 (10.3%) 6 (22.2%)
Antiarrhythmics 58 (33.5%) 46 (31.5%) 12 (44.4%)
Hypertension 62 (35.8%) 53 (36.3%) 9 (33.3%)
Reduced ejection fraction (≤ 40%) 3 (1.7%) 3 (2.1%) 0 (0%)
Pathologic electrocardiogram 51 (29.5%) 45 (30.8%) 6 (22.2%)
Valvular heart disease 11 (6.4%) 10 (6.8%) 1 (3.7%)
Abnormal B-type natriuretic peptide 47 (27.2%) 41 (28.1%) 6 (22.2%)
Ventricular hypertrophy ≥ 15 mm 2 (1.2%) 2 (1.4%) 0 (0%)
Ischemic heart disease 22 (12.7%) 20 (13.7%) 2 (7.4%)
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tored during a total of 104,685 days (286.6 years). The 
mean follow-up was 605 ± 409 days. The decision to 
explant was based on the physician’s judgment who 
decided an evaluation sufficient to reach a definite 
endpoint, such as device implant (pacemaker/ICD), 
initiation of pharmacological regimen, dosage changes 
to an existing drug regimen, electrophysiology study 
and ablation, patient death, or reassurance. It is note-
worthy that several patients were monitored by ILR 
for more than 3 years, which is the estimated device 
longevity as reported by the manufacturer. 
Outcome
The outcome of the ILR evaluation is depicted 
in Figure 1 as cumulative incidence with regard to 
time from implant. A total of 39 patients with syn-
cope experienced a clinically relevant arrhythmia 
(sinus arrest/bradycardia, atrioventricular block, 
asystolia) and were recommended implantation of 
a permanent pacemaker (DDDR, VVIR, and AAIR 
devices in 29, 9, and 1 patients, respectively). In ad-
dition, 2 patients received an ICD due to ventricular 
tachycardia. This amounts to 28.1% who received 
a pacemaker or ICD during the total follow-up.
The cumulative incidence of pacemaker/ICD 
implant at 6, 12, and 18 months were 8.8%, 21.3%, 
and 26.7%, respectively. This time-to-event analy-
sis is graphically presented in Figure 1. 
Predictors 
The only predictor of pacemaker/ICD outcome 
which correlated significantly with outcome was 
age > 75 years. No other predictors of pacemaker/
ICD outcome (male sex, age > 75 years, history 
of trauma at a syncope episode, ischemic heart 
disease, hypertension, antiarrhythmic agents 
(including beta-blockers), prodromal symptoms, 
stroke, ECG pathology, or abnormal heart failure 
marker (B-type natriuretic peptide/N-terminal 
pro-BNP [BNP/NT-proBNP]) correlated signifi-
cantly (p < 0.05) with outcome. The relative risk 
for pacemaker/ICD implant in patients aged > 75 
years was 44%. A tendency for increased relative 
risk (p < 0.20) was observed for patients with 
a history of trauma (17%) and abnormal BNP/NT-
-proBNP levels (25%), while sex, ischemic heart 
disease, antiarrhythmic agents, prodromal symp-
toms, stroke, and pathologic ECG did not. None 
of these dichotomized categorical variables were 
significantly associated with outcome in univariable 
or multivariable analysis. The association between 
predictors and pacemaker/ICD outcome using 
a logistic regression model is summarized in Table 3. 
Table 2. Diagnostics tools used before implantable loop recorder evaluation with regard to syncope 
and miscellaneous indications.
Variables All patients (n = 173) Syncope (n = 146) Miscellaneous (n = 27)
Holter 108 (62.4%) 87 (59.6%) 21 (77.8%)
Exercise test 98 (56.6%) 81 (55.5%) 17 (63.0%)
Active standing test 89 (51.4%) 87 (59.6%) 2 (7.4%)
Head computer tomography 79 (45.7%) 76 (52.1%) 3 (11.1%)
Electroencephalogram 58 (33.5%) 58 (39.7%) 0 (0%)
Carotid sinus massage 27 (15.6%) 27 (18.5%) 0 (0%)
ZenicorTM (external loop recorder) 14 (8.1%) 5 (3.4%) 9 (33.3%)
Electrophysiological study 13 (7.5%) 8 (5.5%) 5 (18.5%)
External loop recorder 5 (2.9%) 4 (2.7%) 1 (3.7%)
Head-up tilt test 4 (2.3%) 4 (2.7%) 0 (0%)
Figure 1. Kaplan-Meier curve of pacemaker/implantable 
cardioverter-defibrillator (ICD) outcome after implant-
able loop recorder evaluation.
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In a multivariable analysis using predictors 
from the univariable analysis with p ≤ 0.100 results, 
only advanced age > 75 years emerges as a sig-
nificant predictor; the same holds true if variables 
with significance level of p ≤ 0.200 are included.
Arrhythmias or other clinical scenarios were 
detected in a substantial portion of patients who 
had a miscellaneous indication for an ILR. In 
patients with a non-syncope indication for ILR, 
2 patients received a pacemaker.
None of the analyzed patients had acomplica-
tion (i.e. infection) leading to premature explanta-
tion.
Deaths during ILR monitoring
In total, 6 patients died while being monitored 
by an ILR. One elderly patient with asymptomatic 
second-degree atrioventricular block Mobitz type II 
during gastroenteritis who died in the Emergency 
Department of cardiac arrest. One elderly patient 
with several comorbidities living in a nursing 
home had a history of suspected post-apoplectic 
epilepsy and died suddenly. The ILR of another 
elderly patient with polyneuropathy revealed 4 s 
of asystole at death. Two other patients with se-
vere comorbidities died from metastatic cancer. 
A young patient with a phenotype of type 1 long QT 
syndrome and QT duration greater than 500 ms 
despite 200 mg daily dosage of metoprolol therapy 
died suddenly and postmortem analysis confirmed 
the expected serum concentration of metoprolol; 
the cause of death was attributed to polymorphic 
ventricular arrhythmia. 
Discussion
Syncope was the indication that led to the 
vast majority of ILR evaluations in this study and 
about a third (28.1%) of patients with a history 
of unexplained presyncope or syncope went on 
to eventually receive a pacemaker or ICD after 
a thorough diagnostic work-up. The present findings 
fall in the higher end of results obtained from prior 
studies, where a 19% to 27% bradyarrhythmic eti-
ology of syncope was observed [7, 8, 15, 19, 20]. It 
is important to note that the time span from ILR 
implantation until the point at which a clinically 
relevant arrhythmia is recorded can vary markedly 
among patients. This underscores the highly un-
predictable course of cardiac syncope. A prior study 
reported that more than 1.5 years was needed for 
the ILR to capture clinically relevant information in 
about a quarter of syncopal or presyncopal patients 
[20]. Therefore, monitoring strategies should take 
a long-term view and devices should be able to 
monitor patients for a prolonged period of time.
In the largest prospective study to date of the 
use of ILRs in patients with unexplained syncope, 
15.1% of patients received pacemakers, 6% ICDs, 
and 78% had overall guidance to diagnosis [11]. 
In the Spanish Reveal Registry, 31% of patients 
were treated according to ILR findings, of whom 
21.3% received a pacemaker and 1.6% an ICD [17]. 
A randomized study of unexplained syncope patients 
found that 15.4% of patients (6/39) in the ILR 
group ended up being implanted with a pacemaker 
[21]. In an observational study at a tertiary care 
Table 3. Predictors of pacemaker or implantable defibrillator outcome among 146 patients evaluated 
with an implantable loop recorder due to syncope/presyncope.
Variable Univariable analysis Multivariable analysis
N (%) OR 95% CI P OR 95% CI P
Age > 75 years 37 (25%) 3.01 1.37–6.63 0.010 2.61 1.10–6.24 0.031
Male sex 67 (46%) 1.03 0.50–2.12 1.000
Trauma 51 (35%) 1.71 0.81–3.59 0.179 0.59 0.28–1.27 0.592
Stroke 14 (10%) 2.08 0.67–6.41 0.218
Ischemic heart disease 20 (14%) 1.11 0.40–3.13 0.795
Hypertension 53 (36%) 1.02 0.48–2.15 1.000
Antiarrhythmics 46 (32%) 1.19 0.55–2.55 0.695
Prodromal symptom 67 (46%) 1.03 0.50–2.12 1.000
Pathologic electrocardiogram 45 (31%) 1.68 0.79–3.58 0.231
Abnormal BNP 41 (28%) 2.05 0.95–4.43 0.100 0.72 0.30–1.71 0.450
BNP — B-type natriuretic peptide; CI — confidence interval; OR — odds ratio
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center in France, 21.1% of patients (20/95) with 
recurrent syncope received permanent pacemak-
ers [15]. Two Italian studies from tertiary centers 
yielded pacemaker implant in 19.0% (11/58) [22] 
and 19.6% (11/56) [16], respectively. A recent 
British study from a university hospital reported 
16.5% of patients (n = 200) received pacemaker 
implants following ILR evaluation [14].  The pre-
sent cohort had a higher proportion of permanent 
device implantation, even though the mean age in 
this study was lower than in the above-mentioned 
studies. However, the present study had a substan-
tial subset of patients older than 75 years and this 
subgroup also had a significantly higher odds ratio 
for this outcome (device implantation). The sex 
distribution of our study was similar to these other 
studies. The lower proportion of pacemaker/ICD 
implantations that occurred in prospective studies 
may be explained by individual study requirements 
to adhere to a specific protocol, whereas in our 
study and in the Spanish Registry, clinicians were 
not obligated to follow any specific protocol [17]. 
This may mean that this study had higher specific-
ity, on the one hand, but lower sensitivity on the 
other, in that guidelines related to device implant 
[6] are not rigorously translated into actual clinical 
practice [23]. 
Advanced age has been identified as a pre-
dictor of pacemaker/ICD outcome [22, 24, 25], 
which may be associated with an abnormal ECG 
and heart failure/structural heart disease [7, 26]. 
When syncope is caused by a sudden-onset ar-
rhythmia resulting in cerebral hypoperfusion and 
abrupt loss of postural tone, trauma is more likely 
than with syncope caused by other mechanisms. 
In several studies, a history of trauma has been 
associated with cardiac syncope [14, 27, 28]. This 
study tended toward those findings, too. However, 
in a multivariable analysis only age > 75 years 
fulfilled statistical significance of p < 0.05, which 
highlights the difficulties in using predictors for 
clinical decision-making.
The Spanish Registry and the prospective 
PICTURE study show that diagnostic episodes 
often occur a year or more after ILR implant [11, 
17]. The unpredictability of cardiac arrhythmias is 
vividly illustrated by the time-to-event analysis 
depicted in Figure 1 and support findings from an-
other recent study analyzing pacemaker outcomes 
[16]. This clinically important finding supports the 
value of longer monitoring periods and advocates 
for the use of ILRs that can provide three or even 
more years of information. The extra resources 
required for extended follow-up may be met in 
part by nurse specialists and remote monitoring 
capabilities, making prolonged ILR evaluations cost 
effective [29]. The role of external loop recorders, 
which extend the conventional 24 h to 48 h capac-
ity of Holter monitors, may be expanding as the 
syncopal population is a heterogeneous one; for 
example, external loop recorders may be appro-
priate first-line devices for patients experiencing 
palpitations or with suspected AF. Recent advances 
in software technology and photopletysmographic 
technology for monitoring AF may open the door to 
diagnostic tools such as smart-watches in disease 
management of certain patients [30]. 
The clinical management of patients with 
syncope, palpitations, AF, and dizziness remains 
challenging. These conditions require a multidis-
ciplinary approach and increased knowledge among 
healthcare providers along the whole continuum of 
care for these patients. A knowledge and apprecia-
tion of each diagnostic tool and its individual role 
in syncopal evaluation is crucial in order to achieve 
optimal outcomes [31]. In this study, only 5.5% of 
patients underwent an electrophysiologic study, 
which reflects the unselected nature of this patient 
cohort. The present study was retrospective and 
thus there was no prospective protocol or algorithm 
for physicians to follow in guiding their work-flow. 
The same is probably true for HUT (2.7%) and its 
diminishing role as reflected in the guidelines. In 
contrast, syncope was initially evaluated in this 
study by exercise testing (55.5% of patients) and/ 
/or CT of the skull (52.1%), which aligns with find-
ings from the PICTURE trial [11]. These tests or 
scans were not actually indicated in many cases. 
For example, CT of the skull was often performed 
without signs of focal neurological signs, suspicion 
of epilepsy, or to exclude bleeding secondary to 
trauma. This use of CT scans might expose patients 
to unnecessary radiation and also represents an 
overuse of resources. Finally, it must be stressed 
that ILR solely offers diagnostics, not treatment, 
and risk stratification should be based on current 
guidelines, which sometimes recommend pace-
maker or ICD implantation without the preceding 
finding of an arrhythmia [12, 13]. In fact, according 
to the guidelines for patient risk stratification, the 
patient with a long QT syndrome should have been 
considered for an ICD [13].
Strengths and weaknesses
The data from this triple-center observational 
study of ILR without referral center bias were ret-
rospectively collected and validated. The advantage 
of this pragmatic approach is that clinical decision-
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making was not influenced by any management 
algorithms for inclusion and follow-up. In Sweden, 
all citizens are covered by national health insurance 
which includes ILRs making any socioeconomic 
impact on disease management less likely. Still, 
the ILR device may be considered costly, making 
some degree of patient selection necessary; it is 
unclear how this may have influenced the present 
study. Although this is a rather large ILR study, 
the sample size limits the study in terms of any 
interpretation of how predictors might be associ-
ated with outcomes. 
Conclusions
In syncope evaluation in an unselected cohort 
of ILR patients, 28.1% required a pacemaker or 
an ICD due to the diagnosis of an arrhythmia. 
Advanced age was the only significant predictor 
for arrhythmia requiring device therapy. Time 
to diagnosis is unpredictable and prolonged ILR 
monitoring is warranted in addition to the optimal 
use of other diagnostic tools.
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